Wikipedia -WSS

Wikipedia

author：fashion 2025-10-01 23:38:59 - browse：47631

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Pregnant women don't need prenatal multivitamins, study concludes

focus

WSS

Heart disease and mental health: A look at cardiac psychology

The untold story of TV’s first prescription drug ad

Streamlined flu vaccines recommended by FDA advisory panel

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Readout Newsletter: BridgeBio, Akero, and human embryo models

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

entertainment

Wikipedia

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Alkermes shareholders re

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Activists slam private health insurers over coverage restrictions

A new approach to psychiatric drug development

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

State of the Union pitch: Bigger Medicare drug price negotiations

entertainment

Ozempic has benefits for kidney disease as well as diabetes

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

State of the Union pitch: Bigger Medicare drug price negotiations

DeSantis can now import cheaper drugs. But will Biden get credit?

focus

hotspot

focus

entertainment